Haleon Netherlands Capital B.V., founded in 2022 and located in the Netherlands, operates as a subsidiary of Haleon plc, focusing on the health and wellness sector. The company specializes in the development and distribution of consumer health products, including well-known brands in oral health, pain relief, and vitamins.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| HALEON 1.25% 2026-03-29 EURHaleon Netherlands Capital B.V. | Ireland | 2026-03-29 | 1.250 | 2.40 |
| HALEON 1.75% 2030-03-29 EURHaleon Netherlands Capital B.V. | United Kingdom | 2030-03-29 | 1.750 | 3.05 |
| HALEON 2.13% 2034-03-29 EURHaleon Netherlands Capital B.V. | Netherlands | 2034-03-29 | 2.125 | 3.53 |
| HALEON 3.38% 2038-03-29 GBPHaleon Netherlands Capital B.V. | Germany | 2038-03-29 | 3.375 | 5.61 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Since its inception, Haleon Netherlands Capital B.V. has actively engaged in bond issuances to support its operational and strategic goals. Notably, in 2022, it launched its inaugural bond offering, raising €1 billion with a favorable long-term yield of 2.5%, demonstrating a competitive edge within the industry. This offering, which featured callable options, was well-received in the market, reflecting investor confidence in Haleon's growth strategy and commitment to sustainability initiatives. Recent announcements indicate plans for additional issuances to further enhance capital structure, aligning with evolving market dynamics.